Cerus Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Cerus hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	1.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$0.17
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 05

Here's Why Cerus (NASDAQ:CERS) Can Afford Some Debt

Apr 12

Cerus Corporation (NASDAQ:CERS) Stock Rockets 29% But Many Are Still Ignoring The Company

Mar 07

Slammed 29% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

Jan 18

Health Check: How Prudently Does Cerus (NASDAQ:CERS) Use Debt?

Oct 06

Is Cerus (NASDAQ:CERS) A Risky Investment?

Jul 07

Slammed 32% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

May 12

Cerus: Technical Support Fades, Investment Case Weakens (Technical Analysis)

Sep 29

Cerus GAAP EPS of -$0.05 beats by $0.02, revenue of $47.63M beats by $4.87M

Aug 04

Cerus: Lacks Conviction Against Macro Backdrop, Technicals Supportive Of Near-Term Upside

Jul 14

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von CERS in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von CERS gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Cerus Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von CERS im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (CERS)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Medical Equipment)	1.8%
Analystenprognose in 3 Jahren (CERS)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von CERS im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von CERS im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von CERS, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da CERS keine Ausschüttungen gemeldet hat.

Cerus Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Consensus EPS estimates fall by 29%

The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

First quarter 2024 earnings: EPS misses analyst expectations

Cerus Corporation Reiterates Earnings Guidance for the Year Ending December 31, 2024

Cerus Corporation, Annual General Meeting, Jun 05, 2024

Cerus Corporation to Report Q1, 2024 Results on May 02, 2024

Here's Why Cerus (NASDAQ:CERS) Can Afford Some Debt

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets - Doubling Previous Shelf Life

Consensus EPS estimates fall by 24%, revenue upgraded

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Consensus EPS estimates upgraded to US$0.085 loss, revenue downgraded

Chief Medical Officer notifies of intention to sell stock

No longer forecast to breakeven

Cerus Corporation (NASDAQ:CERS) Stock Rockets 29% But Many Are Still Ignoring The Company

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cerus Corporation Reiterates Product Revenue Guidance for the Full Year 2024

Cerus Corporation to Report Fiscal Year 2023 Results on Mar 05, 2024

Forecast to breakeven in 2025

Slammed 29% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

Cerus Corporation Provides Revenue Guidance for the Fiscal Year 2024

Price target decreased by 28% to US$4.13

Cerus Corporation has filed a Follow-on Equity Offering in the amount of $96.8 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cerus Corporation Provides Product Revenue Guidance for the Full-Year 2023

Cerus Corporation to Report Q3, 2023 Results on Nov 02, 2023

Health Check: How Prudently Does Cerus (NASDAQ:CERS) Use Debt?

Cerus Corporation Announces the Appointment of Alicia Goodman as Chief Human Resources Officer

Price target decreased by 25% to US$5.75

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Cerus Corporation Revises Revenue Guidance for the Year 2023

New minor risk - Share price stability

Is Cerus (NASDAQ:CERS) A Risky Investment?

Slammed 32% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

Consensus EPS estimates fall by 12%

No longer forecast to breakeven

Cerus Corporation Reiterates Revenue Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Medical Officer exercised options and sold US$71k worth of stock

No longer forecast to breakeven

Cerus Corporation to Report Q4, 2022 Results on Feb 28, 2023

No longer forecast to breakeven

Cerus Corporation Provides Revenue Guidance for the Full Year 2023

Independent Director exercised options to buy US$94k worth of stock.

Price target decreased to US$8.70

No longer forecast to breakeven

Price target decreased to US$8.70

Consensus estimates of losses per share improve by 13%

Price target decreased to US$8.50

Third quarter 2022 earnings released: US$0.048 loss per share (vs US$0.072 loss in 3Q 2021)

Cerus Corporation Revises Revenue Guidance for Full Year 2022

Price target decreased to US$8.50

Cerus Corporation Announces Health Canada Approval for Intercept Blood System for Platelets with Seven-Day Storage

Cerus Corporation to Report Q3, 2022 Results on Nov 03, 2022

Cerus: Technical Support Fades, Investment Case Weakens (Technical Analysis)

Chief Medical Officer notifies of intention to sell stock

Consensus forecasts updated

No longer forecast to breakeven

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cerus Corporation Reiterates Revenue Guidance for the Full Year 2022

Cerus GAAP EPS of -$0.05 beats by $0.02, revenue of $47.63M beats by $4.87M

Cerus Corporation to Report Q2, 2022 Results on Aug 04, 2022

Cerus: Lacks Conviction Against Macro Backdrop, Technicals Supportive Of Near-Term Upside

Cerus Corporation Appoints Hua Shan to its Board of Directors

Is Cerus (NASDAQ:CERS) Using Debt In A Risky Way?

VP of Finance & CFO notifies of intention to sell stock

Price target decreased to US$9.40

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cerus Corporation Revises Product Revenue Guidance for the Full Year of 2022

Insufficient new directors

Cerus Corporation, Annual General Meeting, Jun 01, 2022

Cerus Corporation to Report Q1, 2022 Results on May 05, 2022

Insufficient new directors

VP of Finance & CFO exercised options and sold US$162k worth of stock

Is Cerus (NASDAQ:CERS) Using Debt Sensibly?